Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01393899
Other study ID # A3921084
Secondary ID 2011-001754-28
Status Completed
Phase Phase 2
First received July 12, 2011
Last updated September 24, 2015
Start date March 2012
Est. completion date July 2015

Study information

Verified date September 2015
Source Pfizer
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This study investigates safety and efficacy of CP-690,550 in adult patients with moderate to severe Crohn's disease who completed the double-blind induction treatment in Study A3921083 and achieved clinical response-100 and/or clinical remission (CDAI<150) at Week 8.


Recruitment information / eligibility

Status Completed
Enrollment 178
Est. completion date July 2015
Est. primary completion date July 2015
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- Subjects who met study entry criteria, and who completed Week 8 visit of Induction Study A3921083.

- Subjects who achieve clinical response-100 (reduction in CDAI by 100 points) and/or clinical remission (CDAI<150) in Study A3921083.

- Women of childbearing potential must test negative for pregnancy prior to study enrolment.

Exclusion Criteria:

- Subjects who had major protocol violation (as determined by the Sponsor) in the A3921083 study.

- Subjects likely to require any type of surgery during the study period.

- Fecal culture/toxin assay indicating presence of pathogenic infection.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Placebo
oral tablets twice daily
CP-690,550
oral tablets twice daily
CP-690,550
oral tablets twice daily

Locations

Country Name City State
Australia Monash Medical Centre Clayton Victoria
Australia Nepean Public Hospital Kingswood New South Wales
Australia Royal Melbourne Hospital Melbourne Victoria
Austria AKH Wien Universitaetsklinik fuer Innere Medizin III Wien
Bulgaria 4 MBAL Parvo vatreshno otdelenie Sofia
Bulgaria MBAL Sofiamed OOD, Otdelenie po gastroenterologia Sofia
Canada London Health Sciences Centre - University Hospital London Ontario
Canada McGill University Health Centre - Royal Victoria Hospital Montreal Quebec
Canada Office of Dr. David C. Pearson Victoria British Columbia
Canada Office of Drs. Ranjith Andrew Singh and Jamie D. Papp, Victoria British Columbia
Canada PerCuro Clinical Research Ltd. Victoria British Columbia
Czech Republic Hepato-Gastroenterologie HK, s.r.o. Hradec Kralove
Czech Republic RDG centrum s.r.o. (Radiology only) Hradec Kralove
Czech Republic Medial Pharma spol.s.r.o. (Pharmacy only) Hradec Králové
France Hopital Huriez CHRU de Lille Lille Cedex
France Hôpital Haut-Lévêque/Service d hépato-gastroentérologie Pessac Cedex
Germany Charite - Campus Benjamin Franklin Berlin
Germany Charite - Campus Berlin Mitte Berlin
Germany Charite, Universitaetsmedizin Berlin, Campus Virchow-Klinikum Berlin
Germany Universitaetsklinikum Schleswig-Holstein Kiel
Germany Universitaetsklinikum Ulm, Klinik fuer lnnere Medizin II Ulm
Greece General Hospital of Athens "Evangelismos",1st Gastroenterology Department Kolonaki Athens
Hungary Laboratorium Kft. Fovarosi és Pest Megyei Mikrobiologiai Laboratorium Budapest
Hungary Pannonia Magánorvosi Centrum Kft Budapest
Hungary Peterfy Sandor Utcai Korhaz, Rendelointezet es Baleseti Kozpont, I. sz. Belgyogyaszat Budapest
Hungary Szent Janos Korhaz es Eszak-budai Egyesitett Korhazak/I. Belgyogyaszat es Gastroenterologia Budapest
Hungary Bugat Pal Korhaz Egeszsegugyi Szolgaltato Kozhasznu Nonprofit Kft., Gyongyos
Hungary Laboratórium Kft. Somogy Megyei Mikrobiológiai Laboratórium Kaposvár
Hungary Clinfan Kft. Szekszard
Israel Digestive Disease Institute Jerusalem
Israel Meir Medical Center Kfar Saba
Israel Tel Aviv Sourasky Medical Center Tel -Aviv
Japan Toho University Sakura Medical Center Chiba
Japan Hokkaido P.W.F.A.C Sapporo-Kosei general Hospital Hokkaido
Japan The Hospital of Hyogo College of Medicine Nishinomiya Hyogo
Japan Osaka City University Hospital Osaka
Japan National Hospital Organization Sendai Medical Center Sendai Miyagi
Korea, Republic of ASAN Medical Center,Division of Gastroenterology,Department of Internal Medicine Seoul
Korea, Republic of Samsung Medical Center, Division of Gastroenterology, Department of Internal Medicine Seoul
Korea, Republic of Severance Hospital, Yeonsei University Health System Seoul
Korea, Republic of Severance Hospital, Yonsei University Health System Seoul
Netherlands Academisch Medisch Centrum Amsterdam
Netherlands VU University Medical Center Amsterdam
South Africa Kingsbury Hospital Cape Town Western Cape
South Africa Parklands Medical Centre Durban
Spain Comite Etico de Investigacion Clinica Barcelona
Spain Hospital Clinic de Barcelona Barcelona
Spain Hospital Universitario de La Princesa Madrid
Ukraine Donetsk National Medical University n.a M. Gorky, Faculty of Internal Medicine #2 Donetsk
Ukraine Municipal Institution "Odesa Regional Clinical Hospital", Odesa Regional Centre of Gastroenterology. Odesa
Ukraine Medical Clinical Research Center of Medical Center "Health Clinic" LLC Vinnitsa
United States ACMG Endoscopy Center Anaheim California
United States ACRI - Phase I, LLC Anaheim California
United States Advanced Clinical Research Institute-Phase 1, LLC Anaheim California
United States University of Michigan Health Systems Ann Arbor Michigan
United States Chevy Chase Endoscopy Center Chevy Chase Maryland
United States Metropolitan Gastroenterology Group, PC Chevy Chase Maryland
United States Clinical Research of West Florida, Inc. Clearwater Florida
United States Gasteroenterology Consultants of Clearwater Clearwater Florida
United States West Coast Endoscopy Center Clearwater Florida
United States Cleveland Clinic Cleveland Ohio
United States Investigational Drug Services - University Hospitals Case Medical Center Cleveland Ohio
United States University Hospitals Case Medical Center Cleveland Ohio
United States West Coast Clinical Trials Cypress California
United States Shands Endoscopy Center Gainesville Florida
United States Shands Hospital at the University of Florida Gainesville Florida
United States Shands Medical Plaza and Cancer Center Gainesville Florida
United States University of Florida - College of Medicine Gainsville Florida
United States NYU Langone Long Island Clinical Research Associates Great Neck New York
United States Clinical Research Of The Rockies Lafayette Colorado
United States Gastroenterology Associates of Central Georgia, LLC Macon Georgia
United States Great Lakes Gastroenterology Mentor Ohio
United States The Center for Digestive Health Milwaukee Wisconsin
United States Wisconsin Center for Advanced Research - GI Associates, LLC Milwaukee Wisconsin
United States Gastroenterology Group of Naples Naples Florida
United States Gulfshore Endoscopy Center (Endoscopies Only) Naples Florida
United States Cardiology Consultants Norfolk Virginia
United States Digestive & Liver Desease Specialists Norfolk Virginia
United States Alliance Clinical Research Oceanside California
United States North Florida Gastroenterology Research, LLC Orange Park Florida
United States Internal Medicine Specialists Orlando Florida
United States Premier Medical Group of the Hudson Valley, PC Poughkeepsie New York
United States University of Utah HSC Salt Lake City Utah
United States Cotton-O'Neil Clinical Research Center, Digestive Health Topeka Kansas
United States Center for Digestive Health Troy Michigan
United States Surgical Centers of Michigan Troy Michigan
United States Digestive Health Specialists of Tyler Tyler Texas
United States Endoscopy Center of Tyler Tyler Texas
United States Metropolitan Gastroenterology Group, P C Washington DC Virginia
United States Allegiance Research Specialists, LLC Wauwatosa Wisconsin
United States GI Associates Wauwatosa Wisconsin

Sponsors (1)

Lead Sponsor Collaborator
Pfizer

Countries where clinical trial is conducted

United States,  Australia,  Austria,  Bulgaria,  Canada,  Czech Republic,  France,  Germany,  Greece,  Hungary,  Israel,  Japan,  Korea, Republic of,  Netherlands,  South Africa,  Spain,  Ukraine, 

Outcome

Type Measure Description Time frame Safety issue
Primary The proportion of subjects maintaining clinical response-100, as defined by a decrease in CDAI score at least 100 points from A3921083 baseline, or being in clinical remission, as defined by a CDAI score less than 150, at Week 26. Week 26 No
Secondary The proportion of subjects maintaining clinical response-100 or being in clinical remission at Weeks 4, 8, 12, 20 and 26 from the A3921083 Baseline. Week 4, 8,12,20 and 26 No
Secondary The proportion of subjects maintaining at least a clinical response-100 at Weeks 4, 8, 12, 20 and 26. Week 4, 8,12, 20 and 26 No
Secondary The proportion of subjects in clinical remission at Weeks 4, 8, 12, 20 and 26. week 4, 8, 12, 20 and 26 No
Secondary The proportion of subjects in clinical remission at Weeks 4, 8, 12, 20, and 26 among subjects in clinical remission at baseline of maintenance study. week 4, 8,12, 20 and 26 No
Secondary The proportion of subjects in sustained clinical remission in the maintenance phase. Sustained clinical remission is defined as being in clinical remission at both Weeks 20 and 26. week 20 and 26 No
Secondary The proportion of subjects achieving sustained clinical response in the maintenance phase. Sustained clinical response is defined as having at least a clinical response-100 at both Weeks 20 and 26 from the A3921083 Baseline. week 20 and 26 No
Secondary The proportion of subjects achieving a steroid-free clinical remission at Week 26 of the maintenance phase among subjects on steroids at baseline. week 26 No
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03815851 - Relationship Between Prophylactic Drainage and Postoperative Complications (PPOI) in Crohn's Patients After Surgery N/A
Not yet recruiting NCT06100289 - A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease Phase 3
Completed NCT02883452 - A Phase I Study to Evaluate Pharmacokinetics, Efficacy and Safety of CT-P13 Subcutaneous in Patients With Active Crohn's Disease and Ulcerative Colitis Phase 1
Recruiting NCT04777656 - Use of Crohn's Disease Exclusion Diet on Top of Standard Therapy Versus Standard Therapy Alone in Unstable Pediatric Crohn's Disease Patients. Phase 3
Terminated NCT03017014 - A Study to Assess Safety and Effectiveness of Adalimumab for Treating Children and Adolescents With Crohn's Disease in Real Life Conditions
Recruiting NCT06053424 - Positron Emission Tomography Study of Changes in [11C]AZ14132516 Uptake Following Administration of AZD7798 to Healthy Participants and Patients With Crohn's Disease Phase 1
Recruiting NCT05428345 - A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea
Completed NCT02508012 - Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel Diseases N/A
Not yet recruiting NCT02858557 - The Effect of Diet on Microbial Profile and Disease Outcomes in Patients With Inflammatory Bowel Diseases N/A
Terminated NCT02882841 - MOlecular BIomarkers and Adherent and Invasive Escherichia Coli (AIEC) Detection Study In Crohn's Disease Patients N/A
Completed NCT02542917 - Home Versus Postal Testing for Faecal Calprotectin: a Feasibility Study
Terminated NCT02417974 - Prevention of Recurrence of Crohn's Disease by Fecal Microbiota Therapy (FMT) Phase 2
Completed NCT03010787 - A First Time in Human Study in Healthy Volunteers and Patients Phase 1
Active, not recruiting NCT02316678 - Patient Attitudes and Preferences for Outcomes of Inflammatory Bowel Disease Therapeutics N/A
Completed NCT02265588 - Healthy Approach to Physical and Psychological Problems in Youngsters With IBD (HAPPY-IBD). N/A
Completed NCT02197780 - Head-to-head Comparison of Two Fecal Biomarkers to Screen Children for IBD N/A
Completed NCT02154425 - A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers Phase 1
Completed NCT02193048 - Prospective Evaluation of a Scoring System in Patients Newly Diagnosed With Crohn's Disease
Recruiting NCT02395354 - Comparative Prospective Multicenter Randomized Study of Endoscopic Treatment of Stenosis in Crohn´s Disease N/A
Completed NCT01958827 - A Study of Adalimumab After Dose Escalation in Japanese Subjects With Crohn's Disease Phase 3